1. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab
and bevacizumab for treatment of neovascular age-related macular degeneration: two-year
results. Ophthalmology. 2012;119:1388-98.
4. Lichter JB, Vogel R, Han Y, Bui TV, Singeman LJ. Investigation of oral fenretinide
for treatment of geographic atrophy in age-related macular degeneration. RETINA. 2013;33:498-507.
5. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM,
D'Amico DJ, et al. A phase II randomized double-masked trial of pegaptanib, and anti-vascular
endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747-57.
6. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple
intravitreal injections of ranibizumab in patients with center-involving clinically
significant diabetic macular edema. Ophthalmology. 2006;113:1706-12.
7. Jardeleza MS, Miller JW. Review of anti-VEGF therapy in proliferative diabetic
retinopathy. Semin Ophthalmol. 2009;24:87-92.
8. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP,
Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study):1
12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes
Care. 2010;33:2399-405.
9. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab
on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130:1145-52.
10. Adamis AP, Altaweel M, Bressler NM, Cunningham ET Jr, Davis MD,
Goldbaum M, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy
in diabetic individuals. Ophthalmology. 2006;113:23-8.
11. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N,
Rundle AC, et al. Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion. Six-month
primary end point results of a phase III study. Ophthalmology. 2010;117:1102-12.
12. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab
for Macular Edema following Central Retinal Vein Occlusion. Six-month primary end
point results of a phase III study. Ophthalmology. 2010;117:1124-33.
13. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R,
Berliner AJ, et al. Intravitreal Aflibercept Injection for Macular Edema Secondary to Central
Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS study. Am J Ophthalmol.
2013;155:429-37.
15. Folgar FA, Toth CA, DeCroos FC, Girach A, Pakola S,
Jaffe GJ. Assessment of Retinal Morphology with Spectral and Time Domain OCT in the Phase
III Trials of Enzymatic Vitreolysis. Invest Ophthalmol Vis Sci. 2013;53:7395-401.
16. Fileta JB, Scott IU, Flynn HW Jr. Meta-analysis of infectious endophthalmitis
after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic
Surg Lasers Imaging Retina. 2014;45:143-9.
17. Rayess N, Rahimy E, Storey P, Shah CP, Wolfe JD,
Chen E, et al. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal
Bevacizumab, Ranibizumab, and Aflibercept. Am J Ophthalmol. 2016;165:88-93.
18. Yokoyama K, Choshi T, Kimoto K, Shinoda K, Nakatsuka K. Retinal circulatory disturbances
following intracameral injection of bevacizumab for neovascular glaucoma. Acta Ophthalmol. 2008;86:927-8.
19. Karabag RY, Parlak M, Cetin G, Yaman A, Osman Saarci A. Retinal tears and rhegmatogeous
retinal detachment after intravitreal injections: its prevalence and case reports.
Digit J Ophthalmol. 2015;21:8-10.
20. Avery RL, Gordon GM. Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial
Growth Factor Therapy for Diabetic Macular Edema. JAMA Ophthalmol. 2016;134:21-9.
21. Yashuda S, Kachi S, Ueno S, Piao CH, Terasaki H. Flicker electroretinogram before
and after intravitreal ranibizumab injection in eyes with central retinal vein occlusion.
Acta Ophthalmol. 2015;93:e465-8.
22. Holm K, Schroeder M, Lövestam AM. Peripheral retinal function assessed with 30-Hz
flicker seems to improve after treatment with Lucentis in patients with diabetic macular
oedema. Doc Ophthalmol. 2015;131:43-51.
23. Andrade GC, Dias JR, Maia A, Farah ME, Meyer CH,
Rodrigues EB. Intravitreal injection of ziv-aflibercept for diabetic macular edema: A pilot Study.
Retina. 2016;36:1640-5.
24. Nakamura N, Fujinami K, Mizuno Y, Noda T, Tsunoda K. Evaluation of cone function
by a handheld non-mydriatic flicker electroretinogram device. Clin Ophthalmology.
2016;10:1175-85.
25. Kato K, Kondo M, Sugimoto M, Ikesugi K, Matsubara H. Effect of Pupil Size on
Flicker ERGs Recorded with RETeval System: New Mydriasis-Free Full-Field ERG System.
Invest Ophthalmol Vis Sci. 2015;56:3684-90.
26. Skaat A, Solomon A, Moroz I, Hai OV, Rechtman E, Vishnevskia Dai V, et al. Increased
electroretinogram a-wave amplitude after intravitreal bevacizumab injection for neovascular
age-related macular degeneration Acta Ophthalmol. 2011;89:e269-73.
27. Kato K, Kondo M, Nagashima R, Sugawara A, Sugimoto M, Matsubara H, et al. Factors Affecting Mydriasis-Free Flicker ERGs Recorded With Real-Time Correction for Retinal Illuminance: Study of 150 Young Healthy Subjects. Invest Ophthalmol Vis Sci. 2017;58:5280-6.
28. Severns ML, Johnson MA, Merritt SA. Automated estimation of implicit time and amplitude
from the flicker electroretinogram. Appl Opt. 1991;30:2106–12.
29. Januschowski K, Schnichels S, Hagemann U, Koch V, Hofmann J,
Spitzer MS, et al. Electrophysiological toxicity testing of VEGF Trap-Eye in an isolated perfused
vertebrate retina organ culture model. Acta Ophthalmol. 2014;92:e305-11.
30. Myers AC, Lövestam Adrian M, Bruun A, Ghosh F, Andreasson S,
Ponjavic V. Retinal Function and Morphology in Rabbit After Intravitreal Injection of VEGF Inhibitors.
Curr Eye Res. 2012;37:399-407.
31. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic
pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or
aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98:1636-41.
32. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic
pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and
ranibizumab. Retina. 2017;37:1847-58.
33. Miyake Y, Yagasaki K, Horiguchi M. Electroretinographic monitoring of retinal
function during eye surgery. Arch Ophthalmol. 1991:109;1123-6.
34. Miyake Y, Horigchi M. Electroretinographic alterations during vitrectomy in human
eyes. Graefe’s Arch Clin Exp Ophthalmol. 1998:236;13-7.
35. Yagura K, Shinoda K, Matsumoto S, Terauchi G, Kawashima M, Watanabe E, et al.
Electroretinographic evaluations of retinal function before, just after, and after
intravitreal injections. Sci. Rep. 2016:6;31104.
36. Horiguchi M, Miyake Y. Effect of temperature on electroretinography readings
during closed vitrectomy in humans. Arch Ophthalmol. 1991:109;1127-9.